ATG2B and non-small cell lung carcinoma: Also, in NSCLC, miR-143 targets ATG2B and miR-34a targets TGFβR2 to inhibit cell proliferation [49,50]; Besides, serum miR-126 and miR-21 levels can be used as novel biomarkers in non-small cell lung cancer development, metastasis and screening [51,52], and circulating miR-29a shows a highly prognostic signature in non-squamous NSCLC patients [53].